Blockchain Registration Transaction Record

Regentis Biomaterials to Present at 2026 ThinkEquity Conference

Regentis Biomaterials CEO Ehud Geller to present at 2026 ThinkEquity Conference, highlighting GelrinC® technology, Phase III trial progress, and European commercialization plans.

Regentis Biomaterials' participation in the ThinkEquity Conference comes at a pivotal time as the company advances its GelrinC technology through a Phase III trial and prepares for European commercialization. With no off-the-shelf treatment currently available for cartilage knee repair in the U.S., GelrinC could fill a significant gap in orthopedic care, potentially improving outcomes for hundreds of thousands of patients annually. The CE Mark approval in Europe validates the technology's safety and efficacy, positioning Regentis for near-term revenue generation. Investors should take note: successful trial results and market entry could drive substantial growth, making this a compelling story in the regenerative medicine space.